Susquehanna International Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-12,900
Closed -$16.4K 13746
2023
Q3
$16.4K Buy
+12,900
New +$11.3K ﹤0.01% 11648
2022
Q1
Sell
-92,700
Closed -$267K 14296
2021
Q4
$267K Sell
92,700
-24,700
-21% -$91.4K ﹤0.01% 10767
2021
Q3
$498K Sell
117,400
-101,700
-46% -$454K ﹤0.01% 9416
2021
Q2
$1.16M Sell
219,100
-161,000
-42% -$774K ﹤0.01% 7355
2021
Q1
$1.77M Buy
380,100
+197,300
+108% +$894K ﹤0.01% 6227
2020
Q4
$603K Buy
182,800
+10,600
+6% +$40.3K ﹤0.01% 7878
2020
Q3
$570K Sell
172,200
-89,500
-34% -$329K ﹤0.01% 7405
2020
Q2
$882K Sell
261,700
-89,100
-25% -$421K ﹤0.01% 6200
2020
Q1
$1.34M Sell
350,800
-98,300
-22% -$457K ﹤0.01% 4717
2019
Q4
$2.71M Buy
449,100
+137,600
+44% +$941K ﹤0.01% 3853
2019
Q3
$2.35M Sell
311,500
-226,400
-42% -$2.55M ﹤0.01% 3888
2019
Q2
$7.29M Buy
537,900
+343,200
+176% +$3.96M ﹤0.01% 2248
2019
Q1
$1.05M Buy
194,700
+6,400
+3% +$31.1K ﹤0.01% 4940
2018
Q4
$559K Sell
188,300
-98,500
-34% -$539K ﹤0.01% 5806
2018
Q3
$2.34M Buy
286,800
+137,100
+92% +$1.05M ﹤0.01% 3749
2018
Q2
$1.46M Buy
149,700
+35,800
+31% +$367K ﹤0.01% 4595
2018
Q1
$990K Sell
113,900
-26,600
-19% -$287K ﹤0.01% 5260
2017
Q4
$1.76M Sell
140,500
-73,700
-34% -$845K ﹤0.01% 4144
2017
Q3
$1.79M Sell
214,200
-143,400
-40% -$1.52M ﹤0.01% 4117
2017
Q2
$6.07M Buy
357,600
+329,100
+1,155% +$6.54M ﹤0.01% 2179
2017
Q1
$573K Buy
+28,500
New +$566K ﹤0.01% 6245

Susquehanna International Group's ZYNE Position: Q4 2023 in Review

Susquehanna International Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 221,719 shares — an estimated $282K sold.

Susquehanna International Group first reported a position in ZYNE in Q4 2017 and held it in 18 quarters. The position peaked at $2.69M in Q3 2018. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

  • Susquehanna International Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • Susquehanna International Group sold 221,719 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $282K.
  • Susquehanna International Group first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 18 quarters.
  • Susquehanna International Group's Zynerba Pharmaceuticals, Inc position peaked at $2.69M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.